On October 31, 2019 Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported it will host an investor event to review the full safety, clinical efficacy, and biomarker data from Part 1 of the Phase 1/2 clinical trial of RP1 alone and in combination with Opdivo (Press release, Replimune, OCT 31, 2019, View Source [SID1234550115]). The event will include a presentation by Robert Coffin, Ph.D., President and CEO of Replimune who will be joined by the principle investigator, Mark Middleton, MD, PhD, Professor of Experimental Cancer at the University of Oxford, and other senior members of the Replimune management team. The presentation will focus on the data being presented at SITC (Free SITC Whitepaper) as well as additional supporting data from the clinical trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will begin at 6:30 p.m. Eastern Time on Friday, November 8, 2019 in National Harbor, MD.

A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for 30 days following the conference.